Lyophilisation Conference 2019

SMi Group3 - 4 June 2019, London, UK
SMi Group announces the return of the 7th Annual Lyophilisation Conference. Lyophilisation (or freeze drying) remains one of the most exciting and rapidly advancing technologies in the pharmaceutical industry to date. By 2020, the lyophilisation equipment market is projected to exceed 8% CAGR reaching approximately £4.4 billion.

Attend this conference along with key opinion leaders from all areas of pharmaceuticals and biologicals to explore formulation science, materials characterisation, novel and alternative technologies, mathematical modelling and regulatory updates.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2019

  • Sune Klint Andersen, Principal Spray Drying,Janssen Pharmaceuticals
  • Xiaodong Chen, Senior Research Investigator,Bristol-Myers Squibb

Key Speakers include

  • Paul Matejtschuk, Principal Scientist & Section Head, Standardisation Science, NIBSC
  • Davide Fissore, Associate Professor, Politecnico di Torino
  • Michael Dekner, Head Fill & Finish LCM support, Takeda
  • Richard Denk, Head Sales Containment, Skan AG
  • Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis R&D
  • Daryl Williams, Professor of Particle Science and Director of Discovery space, Imperial College London
  • Kevin Ward, Director of R&D, Biopharma technology
  • Paul Barry, Development Scientist, Genzyme Ireland Ltd/Sanofi

2019 Highlights

  • Explore the recent advances in lyophilisation methods and technologies from Biopharma Technology
  • Discuss the novel methods that characterise complex pharmaceutical products to aid formulation design from NIBSC
  • Gain insight into the approaches to avoid cross contamination during lyophilisation from SKAN AG
  • Discover a new approach towards process design through the use of micro freeze dryers by Politecno di Torino
  • Examine the use of model-based approach to lyophilisation cycle design from Takeda

For further information and to register, please visit:
http://www.lyophilisation-europe.com/wpnwe

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...